Optimizing antibiotic treatment for ventilator-associated pneumonia

Pharmacotherapy. 2006 Feb;26(2):204-13. doi: 10.1592/phco.26.2.204.

Abstract

Ventilator-associated pneumonia (VAP) is the most common infectious complication in patients receiving mechanical ventilation and accounts for exorbitant use of resources in the intensive care unit. Antimicrobial management of VAP incorporates an initial broad-spectrum, empiric regimen to ensure appropriate coverage with deescalation of therapy after 48-72 hours based on culture results and sensitivities. When VAP clinically responds to treatment, antimicrobials should be discontinued after 7-8 days to reduce overall antibiotic consumption and the selection pressure on flora observed in the intensive care unit and thus minimize the development and spread of antimicrobial resistance.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / pharmacokinetics
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use*
  • Bacteria / drug effects
  • Cross Infection / diagnosis
  • Cross Infection / drug therapy*
  • Cross Infection / etiology*
  • Cross Infection / microbiology
  • Humans
  • Pneumonia / diagnosis
  • Pneumonia / drug therapy*
  • Pneumonia / etiology*
  • Pneumonia / microbiology
  • Respiration, Artificial / adverse effects*
  • Ventilators, Mechanical / adverse effects*

Substances

  • Anti-Bacterial Agents